Rigorous Assessment of P. vivax Relapses and Primaquine Efficacy for Radical Cure

严格评估间日疟原虫复发和伯氨喹根治疗效

基本信息

批准号：
10219069
负责人：
David Serre
金额：
$ 63.96万
依托单位：
UNIVERSITY OF MARYLAND BALTIMORE
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-07-17 至 2025-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10219069
关键词：
Address Adherence Africa Alleles Area Biology Blood Blood specimen CYP2D6 gene Cambodia Chloroguanide Collaborations Collection Country Detection Development Dose Drug Kinetics Enrollment Erythropoiesis Falciparum Malaria Fingers Frequencies G6PD gene Gene Expression Genes Genetic Polymorphism Genome Genomic approach Genomics Genotype Human In Vitro Incidence Individual Infection Inflammation Laboratories Liver Malaria Metabolism Modernization Morbidity - disease rate Parasites Patients Pattern Pharmaceutical Preparations Plasmodium falciparum Plasmodium vivax Population Predisposition Primaquine Primary Infection Proteins Proxy Recrudescences Regimen Relapse Retreatment Sepsis Serology Sporozoites Testing Time Variant Vivax Malaria Work atovaquone clinically relevant design efficacy evaluation field study genome sequencing improved insight patient subsets response side effect transmission process whole genome

项目摘要

Plasmodium vivax threatens half of the world’s population. While on-going malaria elimination efforts are successfully reducing the burden of falciparum malaria worldwide, the situation is much less promising for P. vivax. In particular, the unique ability of P. vivax parasites to remain dormant in the liver and cause relapse infections weeks or months later greatly complicates malaria elimination campaigns. Here we propose to conduct a tightly-controlled field study in Cambodia, specifically designed to support and empower state-of-the-art genomic analyses, to determine the frequency of relapse and the factors associated with hypnozoite reactivation, as well as to rigorously evaluate the efficacy of different doses of primaquine for radical cure treatment. Our studies will provide a unique perspective on P. vivax relapse and will contribute to better understand how to successfully eliminate this understudied parasite.

Vivax疟原虫威胁到世界一半的人口。而持续消除疟疾的工作是成功地减少了全球恶性疟疾的伯恩的伯宁，这种情况对P. Vivax。特别是，疟原虫寄生虫在肝脏中保持休眠状态的独特能力并引起缓解几周或几个月后的感染极大地使疟疾消除运动复杂化。在这里我们建议进行在柬埔寨进行的严格控制的现场研究，专门为支持和赋予最先进的能力而设计基因组分析，以确定继电器的频率和与催眠症次生症相关的因素，以及严格评估不同剂量的抗抗剂量治疗的效率。我们的研究将为P. Vivax继电器提供独特的观点，并有助于更好地了解如何成功地消除了这种理解的寄生虫。